RxDoctor Payments Data

Bryan Kirkland, MD

Internal Medicine · Monroe, GANPI 1821018441

Payments from drug & device makers

$8,034in general payments, 2019–2025

Across 513 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$821
  • AbbVie$758
  • AstraZeneca$676
  • Pfizer$345
  • Abbott$339
  • plus $4K from 52 others

What the payments were for

  • Food & beverage$7,95199%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk95$1,016
Amgen(2 entities)49$821
AbbVie(2 entities)58$758
AstraZeneca46$676
Pfizer21$345
Abbott18$339
Lilly USA, LLC20$327
Astellas Pharma US Inc11$304
Amarin Pharma, Inc.13$234
Takeda Pharmaceuticals U.S.A., Inc.14$233
GSK15$212
Corcept Therapeutics10$205
Radius Health, Inc.7$197
Merck13$181
Boehringer Ingelheim10$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$161
Exact Sciences9$153
Avanir Pharmaceuticals, Inc.7$122
Johnson & Johnson8$110
Teva Pharmaceuticals USA, Inc.3$109
Dexcom, Inc.5$107
Otsuka America Pharmaceutical, Inc.5$107
Biohaven Pharmaceutical Holding Company Ltd.6$104
Biohaven Pharmaceuticals, Inc.5$88
Paratek Pharmaceuticals, Inc.4$76
ARS Pharmaceuticals Operations, Inc.2$55
Sanofi-aventis U.S. LLC3$53
Idorsia Pharmaceuticals US Inc4$52
Upsher-smith Laboratories LLC3$51
Xeris Pharmaceuticals, Inc.2$44
Axsome Therapeutics, Inc.2$42
Sunovion Pharmaceuticals Inc.2$41
Nestle Healthcare Nutrition Inc.2$41
Sanofi Pasteur Inc.2$35
Eisai Inc.2$31
Mylan Pharmaceuticals Inc.2$30
Sumitomo Pharma America, Inc.2$28
Vanda Pharmaceuticals Inc.1$28
Novartis2$28
Corium, LLC1$25
Esperion Therapeutics, Inc.1$25
E.r. Squibb & Sons, L.L.C.2$25
Phathom Pharmaceuticals, Inc.1$20
Siemens Medical Solutions USA, Inc.1$20
Antares Pharma, Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Endo Pharmaceuticals Inc.1$17
Neos Therapeutics, LP1$17
Biogen1$15
Impel Pharmaceuticals Inc.1$15
Currax Pharmaceuticals LLC1$15
Ironshore Pharmaceuticals Inc.1$15
Acella Pharmaceuticals, LLC1$15
UCB, Inc.1$14
Nalpropion Pharmaceuticals LLC1$14
Lupin Inc.1$13
Seqirus USA Inc1$13
Adlon Therapeutics L.p.1$12

How this compares

$8,034 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$182,577
Medicare patients
248
Services billed
2,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$152,781
EliquisApixaban100$100,656
MounjaroTirzepatide68$94,220
JanuviaSitagliptin Phosphate71$74,898
RybelsusSemaglutide46$68,637
XareltoRivaroxaban76$66,434
JardianceEmpagliflozin50$51,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$46,091
FarxigaDapagliflozin Propanediol41$32,394
MyrbetriqMirabegron30$24,860
LinzessLinaclotide22$23,985
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$19,373
BelsomraSuvorexant12$13,941
Breo ElliptaFluticasone/Vilanterol16$12,905
TrulancePlecanatide16$12,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,016$221,418155 claims
PfizerEliquis$345$100,656100 claims
Lilly USA, LLCMounjaro$327$94,22068 claims
MerckJanuvia, Belsomra$181$88,83983 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$212$78,36996 claims
Johnson & JohnsonXarelto$110$66,43476 claims
Boehringer IngelheimJardiance$166$51,76150 claims
AstraZenecaFarxiga, Breztri Aerosphere$676$39,24452 claims
AbbVieLinzess, Restasis$758$30,03936 claims
Astellas Pharma US IncMyrbetriq$304$24,86030 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$161$12,57116 claims
Sumitomo Pharma America, Inc.Gemtesa$28$7,60815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Monroe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →